Novartis (NOVN) Given a CHF 75 Price Target at Barclays

Barclays set a CHF 75 price objective on Novartis (VTX:NOVN) in a research note published on Friday. The firm currently has a sell rating on the stock.

A number of other research analysts have also issued reports on the stock. UBS set a CHF 80 price objective on shares of Novartis and gave the company a neutral rating in a report on Thursday. Sanford C. Bernstein set a CHF 90 price objective on shares of Novartis and gave the company a buy rating in a report on Thursday. JPMorgan Chase set a CHF 84 price objective on shares of Novartis and gave the company a neutral rating in a report on Tuesday. Berenberg Bank set a CHF 90 price objective on shares of Novartis and gave the company a neutral rating in a report on Monday, April 16th. Finally, Jefferies Group set a CHF 98 price objective on shares of Novartis and gave the company a buy rating in a report on Friday, April 13th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of CHF 87.85.

Shares of VTX NOVN opened at CHF 78.38 on Friday. Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

ILLEGAL ACTIVITY WARNING: “Novartis (NOVN) Given a CHF 75 Price Target at Barclays” was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://transcriptdaily.com/2018/04/21/novartis-novn-given-a-chf-75-price-target-at-barclays.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply